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has been believed that EMR system improved efficacy of the hospital. But a pure 
hospital management/financial meaning of EMR is still not clear. It is said that the 
total costs for maintaining EMR are 2-5% of medical revenue and they are continu-
ously needed. In Japan, in order to increase the efficiency of a clinical trial/research, 
government is planning to set up one big virtual hospital using EMR and IT tech-
nology. In this study, we analyze the change in financial condition and the price of 
EMR system. Methods: From the hospital website and financial statement, we 
checked when and whether EMR was introduced. Then we analyzed the change 
in financial condition of the hospital that introduced EMR with the hospital that 
did not introduce EMR using the financial statements of 143 hospitals in National 
Hospital Organization (NHO). The information of the EMR price was obtained from 
the government website. Results: In 2011, there were 44 hospitals that had intro-
duced EMR. Comparing the financial condition between the hospital with EMR and 
the hospital without EMR, there was 1% or more of difference in medical revenue. 
The average price of EMR for 1 year per 1 bed was US$328.8. ConClusions: The 
result demonstrated that the price of all EMR system did not improve hospital 
finance and efficiency. Because of the high cost EMR system, making one big virtual 
hospital using IT technology is still difficult. Therefore, we need more cost effective 
and easy EMR system.
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objeCtives: To support tariff setting of Diagnosis Related Groups in the 
Netherlands, the hospital services of each patient are systematically collected in 
a national database. This database may also serve as an important data source 
for economic evaluations. Our study assessed the feasibility of the database to 
support economic evaluations. Methods: Treatment costs for acute myocardial 
infarction (AMI) and breast cancer were determined for 2012 from the hospital 
perspective, with the national database as the primary data source. Results: 
Using the national database as a primary data source for economic evaluations 
has several limitations. Firstly, the database does not contain unit costs of hos-
pital services. Thus, we had to rely on alternative data sources such as reference 
prices. Secondly, the establishment of relevant patient-subgroups is not always 
possible because only few clinical parameters are recorded. Although we were 
able to identify relevant patient subgroups for AMI (ST segment vs non-ST seg-
ment elevated patients and PCI vs conventional treatment), this was not possible 
for breast cancer where different stages of disease could not be distinguished. 
Lastly, some resource quantities, such as medications and medical devices, are 
not routinely collected. ConClusions: Using the national database as the input 
of resource quantities in economic evaluations may result in valid cost estimates, 
especially when relevant subgroups can be identified. The cost assessment of AMI 
has proven that the database enables the collection of resource quantities for 
individual patients from a single data source and thus increases the comparability 
of health economic outcomes.
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objeCtives: To evaluate the burden of influenza B in terms of hospitalizations 
and deaths in France. Methods: The analysis of the impact of influenza B used 3 
French databases 1) hospitalization for respiratory diseases, 2) deaths resulting from 
cardiorespiratory disease, and 3) information on circulating strains. The analysis 
covered the period 2003 through to 2011. The study is based on an indirect approach 
of modeling where hospitalization, mortality and virology time series data will be 
extracted as monthly or weekly aggregated information. The numbers of hospi-
talizations and deaths attributable to influenza B were determined from positive 
virological analysis through a regression model (considering all influenza circulat-
ing strains classified by type and subtype) firstly over the total French population, 
and then by age category (0-4 years, 5-12, 15-64, 65 and above). A second method to 
estimate the excess of hospitalizations and deaths during influenza epidemic peri-
ods vs. non-epidemic periods was also used. Results: Over the period 2003-2011, 
nearly 28,000 hospitalizations and 12,000 deaths on average were associated with 
influenza each year. The percentages of hospitalizations and deaths attributable 
to influenza B were 33% (9,200) and 34% (4,000) respectively, amongst the overall 
population. These were observed predominantly in the elderly (> 65 years): 66% of 
hospitalizations and 94% of deaths. The two methods used show similar results, 
with a difference globally of less than 5%. ConClusions: On average each year 
around 9,200 hospitalizations and 4,000 cardiorespiratory deaths are associated 
with epidemics of influenza B in France.
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objeCtives: To identify the long term effects of common symptoms of pregnancy 
and whether these increase the risk of cardiovascular disease or symptoms asso-
ciated with it in women at 21 years after pregnancy. Methods: Data used were 
from the Mater University Study of Pregnancy (MUSP), a community- based pro-
spective birth cohort study begun in Brisbane, Australia, in 1983. Chi square test 
and logistic regression analyses were conducted. Results: Data were available for 
3692 women. In cross tabulations, morning sickness, heartburn and backache show 
patient reported outcomes (PRO). Methods: From the physician universe of the 
IMS®Disease Analyzer (1,500 diabetologists and 57,500 general practitioners), a sub-
set of 101 physicians have agreed to participate. Pre-programmed inclusion criteria 
(i.e. ≥ 18 years old with T2DM diagnosis) triggers consecutive patient selection for 
further data collection. A custom software-based electronic case report form (eCRF) 
is completed once per quarter by the physician to capture further diabetes informa-
tion. Patients complete a validated set of PROs at physician office every 6 months. 
Anonymised data from the electronic medical record (EMR), eCRF and PRO are linked 
through a unique process to ensure patient confidentiality. Results: A total of 1,029 
T2DM patients are contributing to the registry (at June 2014). Preliminary analysis 
of the DIAREG cohort has shown comparable representativeness to IMS®Disease 
Analyzer for several patient characteristics: age, gender, distribution of T2DM treat-
ment and physician type. The DIAREG improves research use of the EMR data by 
filling in missing information for weight, blood pressure and HbA1C (e.g. complete-
ness of HbA1C records improved from 42.3% to 83.3% of patients). The DIAREG 
enhances breadth of information by collecting data that is not normally captured 
in EMR sources, such as physician rationale related to treatment choice or switch, 
target HbA1C, hypoglycaemic events, occurrence of micro or macrovascular events, 
and patient reported information (e.g. quality of life, treatment satisfaction and 
depression). ConClusions: DIAREG enables unique capability to research T2DM 
in Germany through multiple linked longitudinal data sources.
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objeCtives: Health care utilization databases or electronic medical records can be 
very useful to study the use and outcomes of pharmacological and therapeutical 
measures. There is little information on the availability and accessibility of these 
types of databases for health and disease management in the Asian Pacific Region. 
This study is performed to gain more insight in the availability and accessibility 
of health care utilization databases in AsiaPac. Methods: Searches were done 
using Google Scholar, PubMed, ISPOR’s International Digest of Databases and refer-
ences in publications. Different types of databases were included in the overview, 
including health insurance databases, claims databases and electronic medical 
records from primary care of hospitals. Information extracted was: type of database, 
short description, population covered, start of data collection, variables included, 
accessibility, URL and English language yes/no. Countries included were Australia, 
China, Japan, South Korea, Malaysia, Singapore and Thailand. Results: Most of the 
databases originate in Japan and Australia. Taiwan and South Korea have a large 
health insurance databases covering ~98% of the population. Limited number of 
databases is available in the other countries investigated. Accessibility could only be 
derived from the websites that provide an English translation. From these websites 
it appears that accessibility to these databases is often limited for health policy 
makers and researchers due to privacy protection issues. ConClusions: Several 
valuable health care utilization databases exist in the Asian Pacific region. These 
databases could be very valuable in drug utilization and health outcomes research 
if easily available to all researchers.
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objeCtives: The Brazilian Network for Health Technology Assessment (REBRATS) 
spreads the HTA culture in health services and academic institutions, and also 
supports policy makers and managers in the decision-making process. It works 
through six working groups that prioritizes HTA settings and themes; develops 
methodological guidelines; trains professionals; and manage and disseminates 
information. This study aims to demonstrate REBRATS´s advances based on the 
productivity of the network members. Methods: Analysis of the network per-
formance through the number of publications available on the REBRATS data-
base; number of accesses to the REBRATS webpage obtained through the access 
tool and data extraction by Google Analytics, monitoring the participation on the 
REBRATS social networking and computing new network members. Results: 
Since REBRATS´ implementation in 2008, it was made available on its website 62 
publications including Guidelines, HTA Bulletins and others, and 364 studies in 
its database. In 2014, 64 institutions are already member of the network, repre-
senting an increase of over 45% compared to 2008. Additionally, the site began 
to be tracked in mid-2012, when the average number of accesses was 36,659 and 
approximately 2037 per monthly in more than 85 countries. Since March 2012, 
when REBRATS social network on Facebook was created, there have been more 
than 300 published news with approximately 43,891 views and an average of 143 
visualizations per issue reported by the network. ConClusions: The strategies 
for advertising the network and disseminate the HTA products produced by its 
members have contributed significantly to the advance of HTA in Brazil, beyond 
the reach of people interested in this research field. Efforts should be directed 
towards advertising the production internationally.
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objeCtives: Ministry of Health, Labour and Welfare (MHLW) of Japan announced 
the rule about electronic preservation of a medical record in 1999. Then, introduc-
tion of Electric Medical Record (EMR) into a hospital was started. Government set 
a target of diffusion rate of EMR to 60% in 2006, but the result was only 20-30%. It 
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objeCtives: The aim is to compare the drug reimbursement decisions of innova-
tive anti-cancer drugs in five countries (UK, France, Italy, Spain & Australia). Our 
approach was to identify both convergence and divergence in these reimbursement 
decisions and to assess the agreement level between the policy makers. Methods: 
For our analysis we have used 39 oncology drugs authorized by the EMA between 
January 2004 and December 2012 covering a total of 65 indications, and we have 
compared the reimbursement decisions in theses 5 countries. We reviewed the 
technology appraisal performed by their respective national HTA agencies and their 
reimbursement decisions. We have also analyzed the level of agreement for reim-
bursement decisions between pairs of each country with kappa scores. Results: 
Out of these 39 drugs, only 16 drugs were reimbursed in Australia, 15 in England, 
38 in France, followed by Italy and Spain, which respectively reimbursed 29 and 28 
drugs. When we have analyzed the common reimbursement decision taken, we 
have observed that between France and Italy 72% of common positive reimburse-
ment decision were taken, and between France and England only 33 % of positive 
reimbursement decisions are common. In contrast we have found 49 % of common 
negative reimbursement decision between England and Australia. Then we have 
measured the consistency between decision makers with KAPPA scores and it came 
out that France, Italy and Spain are often in agreement in their reimbursement deci-
sions, and that conversely France and England decisions are significantly in disa-
greement. ConClusions: This study demonstrates that the discordance between 
countries reimbursement decisions, in most cases may reflect the differences in 
the decision making process (Eg. France Vs England). But this analysis cannot be 
conclusive. This is why we have carried out further researches using larger datasets 
allowing us to highlight some elements yielding to these reimbursement decision 
differences between countries.
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objeCtives: ISPOR is approaching its 10th anniversary, which offers a suitable occa-
sion to assess the impact of the organization. As the number of members increased, 
the influence of the Board of Directors on scientific discussions also emerged. The 
aim of this research is to present what effect being elected an ISPOR Director has 
on a researcher’s publication activity by using epidemiological methods and data 
mining techniques. Methods: Data on number of publications by year, co-authors, 
titles, abstracts of former ISPOR Directors between 1995 and 2012 were obtained 
from public sources (ISPOR website and PubMed) and analysed by an algorithm 
developed by the authors in R. A case-only study design was applied by matching the 
duration spent as a member of the Board of Directors with the same period prior to 
and after finishing the directorate term. Incidence rate ratios (IRR) were estimated 
by fitting separate Poisson regression models to correct for the baseline increase 
in publication activity. The average number of co-authors and probability of the 
director being the first author was also analysed. Results: The IRR of the period 
preceding to directorate versus the directorate period was 1.59 (CI 95%: 1.34-1.91), 
yielding statistically significant association. The IRR of directorate period versus the 
period succeeding the directorate period was 1.01 (CI 95%: 0.88-1.13). The average 
number of co-authors was the highest after the directorate term (5.94); the probabil-
ity of the director appearing as the first author was the highest prior to directorate 
term (22.91%). ConClusions: As a result of our study, it has been statistically 
proven that being an ISPOR Director does not only provide leadership in a scientific 
organization, but can enhance the members’ career as a researcher. ISPOR Directors 
are more likely to co-author publications even after finishing their directorate term.
ReseARch on MethoDs – Modeling Methods
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objeCtives: Individual simulation is increasingly used in economic models, partly 
because of its capability of predicting event risks based on individual patient char-
acteristics. However, due to lack of individual patient level data, models often use 
means and standard deviations to create patient profiles. The objective of this study 
is to evaluate different simulation approaches of creating patient profile at baseline 
and their impact on model outcomes. Methods: Patient level data (N= 8,857) from 
National Health and Nutrition Examination Survey (NHANES) was used to evalu-
ate three approaches of creating baseline patient profiles for simulation models. 
10 samples of 1000 patients each were created through 1) random sampling from 
patient level data; 2) using means and standard deviations of the profile variables 
without correlating the characteristics; 3) using means and variance-covariance 
matrix among the continuous variable characteristics with cholesky decomposi-
tion approach. 10-year cardiovascular diseases (CVDs) rates are estimated using the 
created patient profiles from these 3 different approaches. Results: The predicted 
CVD rates based on random sampling are 18.2% for males and 9.7% for females using 
the random sampling approach, 14.5% for males and 7.9% for females using the 
mean and standard deviation approach and 16.0% for males and 9.2% for females 
using the cholesky decomposition approach. The CVD rates using the NHANES entire 
positive association (p< 0.05) with different cardiovascular outcomes. However, in 
the multivariate models, only those experiencing heartburn (adjusted OR 1.3, 95% 
CI 1.0-1.7) during pregnancy were at greater risk of having hypertension 21 years 
post partum. Women experiencing morning sickness (adjusted OR 1.2, 95% CI 0.8-
2.0) and backache (adjusted OR 1.1, 95% CI 0.6-1.7) were not considered to be at 
risk for future heart disease. ConClusions: As a whole, our study suggests that 
most common symptoms of pregnancy are not associated with an increased risk 
of cardiovascular disease or with hypertension in the long term.
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objeCtives: Missing values within variables can impede accurate data analysis 
on many levels including both univariate and multivariate analysis. This research 
presents distribution-based imputation (DBI), where the distribution of non-missing 
values is simulated to create a set of values that are then randomly inserted into to 
the missing values in the actual data and compares this against mean based imputa-
tion (MBI). Methods: DBI was compared to MBI in 12 different simulation condi-
tions based on three sample sizes (50, 100, 150 and 200) and three different missing 
value percentages for each of the sample sizes (10%, 20% and 30%). Each simulation 
created 1,000 test datasets within each condition for a total of 12,000 simulated 
datasets. The statistical package, R was used for the sumilation. Results: MBI 
was biased by simulating smaller Standard Deviations, and less accurate in mean 
estimation than DBI in all 12 simulation combinations. DBI was more accurate in 
matching the number of rejected hypotheses as compared to the gold standard. 
Comparing the calculated p-values for bias where an unbiased estimator would 
demonstrate a 50/50 split being greater than and less than the gold standard, DBI 
was closer to the gold standard with at 48.7/51.3 split, as compared to the 25.8/74.2 
split of MBI. ConClusions: DBI was found to be more accurate and unbiased as 
compared to MBI methods. As a result, when studies are small and do not contain a 
large number of variables, or in situations where more elaborate imputation meth-
ods cannot be done, DBI is an accurate and unbiased method.
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objeCtives: To compare ASAS (Assessment in Ankylosing Spondylitis Response 
Criteria) 20 response patterns between anti-TNF biological agents in patients with 
ankylosing spondylitis by means of a mixed treatment comparison of different ran-
domised, controlled trials (RCTs) on the efficacy of biological therapies. Methods: 
A systematic review of literature was performed to identify a number of similarly 
designed double-blind, randomized, placebo-controlled trials investigating the effi-
cacy of the TNF-alfa inhibitors etanercept, infliximab, golimumab, certolizumab 
pegol and adalimumab in the treatment of ankylosing spondylitis patients, con-
ducted over an 18-years period. The endpoint of interest was ASAS20 response 
criteria at 12 weeks. Results were analyzed simultaneously using Bayesian mixed 
treatment comparison techniques. Results were expressed as odds ratio (OR) of 
ASAS20 response and associated 95% credible intervals (CrIs). The probability of 
being the best treatment was also reported. Results: 6 RCTs were selected for data 
extraction and further analysis. By mean of MTC, all anti-TNF agents demonstrated 
to be more efficacious in inducing a ASAS20 response than placebo. Infliximab 
shows a 67,6% of probability of being the best treatment of all. Adalimumab, goli-
mumab and etanercept show probabilities of 17,7%, 10,6% and 4%, respectively, 
while certolizumab pegol showed a probability of being the best treatment of 0,1%. 
No differences were observed when comparing directly an anti-TNFalfa agent 
against another. ConClusions: Even if the mixed treatment comparisons between 
infliximab, golimumab, certolizumab pegol, adalimumab and etanercept did not 
show a statistically signiﬁcant difference, this analysis suggests that infliximab, 
compared to placebo, is expected to provide the highest rate of ASAS20 response 
in SA patients naive to biologic treatments.
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objeCtives: The objective of this presentation will be to introduce the audience 
to various data dimension reduction techniques that may be applied in the setting 
of a large commercial claims data set to facilitate the task of identifying important 
factors or key features for use in subsequent analysis. Methods: The author will 
provide a brief survey of the data dimension reduction literature from areas as 
diverse as image analysis, neural networks, gene expression microarrays, and high 
through-put chemistry to demonstrate that despite that many of these techniques 
have been used in other settings or areas of research, their application to the analy-
sis of health care claims data is relevant and potentially quite useful. Results: 
One, all-purpose, optimal data dimension technique does not exist for application 
in the analysis of health care claims data. The analyst needs to weigh the features 
of the large data set under consideration, the objectives of the downstream or sub-
sequent analysis, and the availability of tools for ease of use and interpretation 
of results. ConClusions: The number of data dimension reduction techniques 
available to claims data set researchers is large and diverse; however, keys features 
of these various approaches can help the analyst make an informed decision that 
is effective with some simple setting and objectives diagnosis.
